PURPOSE: The purpose of this study was to determine the impact of sorafenib on PI3K/AKT/mTOR signaling pathway and to further define its mechanism for treating hepatocellular carcinoma (HCC). METHODS: Human SMMC-7721 hepatic carcinoma cells were treated with or without 4 μmoL/L sorafenib. SMMC- 7721 cells were harvested at various time points (0-48 hrs) and assessed for changes in PI3K, mTOR, and AKT protein and mRNA levels. RESULTS: Human SMMC-7721 hepatic tumor cells exposed to sorafenib had decreased expression of PI3K/mTOR/AKT. CONCLUSION: Sorafenib appears to inhibit hepatic tumor growth by downregulating PI3k/Akt/mTOR signaling pathway.
PURPOSE: The purpose of this study was to determine the impact of sorafenib on PI3K/AKT/mTOR signaling pathway and to further define its mechanism for treating hepatocellular carcinoma (HCC). METHODS:Human SMMC-7721 hepatic carcinoma cells were treated with or without 4 μmoL/L sorafenib. SMMC- 7721 cells were harvested at various time points (0-48 hrs) and assessed for changes in PI3K, mTOR, and AKT protein and mRNA levels. RESULTS:Human SMMC-7721 hepatic tumor cells exposed to sorafenib had decreased expression of PI3K/mTOR/AKT. CONCLUSION:Sorafenib appears to inhibit hepatic tumor growth by downregulating PI3k/Akt/mTOR signaling pathway.
Authors: Mahmoud Ma Elsayed; Mahmoud E Mostafa; Eman Alaaeldin; Hatem Aa Sarhan; Montaser ShA Shaykoon; Shady Allam; Ahmed Rh Ahmed; Bakheet Em Elsadek Journal: Int J Nanomedicine Date: 2019-10-29
Authors: Nestor Prieto-Domínguez; Raquel Ordóñez; Anna Fernández; Andres García-Palomo; Jordi Muntané; Javier González-Gallego; José L Mauriz Journal: Front Pharmacol Date: 2016-06-08 Impact factor: 5.810